Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluarix/Influsplit SSW 2010/2011 Immunogenicity Study
NCT01144299Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Fluarix in influenza (2 arms), sponsored by GSK. Primary endpoints: Hemagglutination Inhibition (HI) Antibody Titer at Day 21, Number of Seroprotected Subjects at Day 21 and 3 more. Started Jun 2010; status: completed.
02
Drugs
Fluarix
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01144299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144299.